Bénin poised to become second francophone leader certified by WHO in healthcare standards

The Bénin has taken a giant leap toward global health recognition. From 6 to 9 July 2026, the Agence Béninoise du Médicament et des autres produits de Santé (ABMed) underwent a rigorous evaluation by a panel of World Health Organization (WHO) experts. This assessment, conducted over four intensive days, has highlighted remarkable progress, bringing the country closer to achieving the prestigious Maturity Level 3 certification—a milestone that would cement nearly a decade of transformative reforms in the healthcare sector.

WHO’s high-stakes evaluation of Bénin’s pharmaceutical governance

A delegation of eight international experts meticulously reviewed every aspect of Bénin’s pharmaceutical regulatory framework. From drug authorization processes to market surveillance, pharmacovigilance, and clinical trials, no stone was left unturned. The audit aimed to assess the country’s alignment with the WHO’s stringent international benchmarks. The results, unveiled on 9 July 2026 in Cotonou, were overwhelmingly positive, signaling a breakthrough in securing the nation’s health supply chain.

Maturity Level 3: What it means for Bénin and its citizens

The Maturity Level 3 (ML3) certification represents a gold standard in pharmaceutical regulation. According to the WHO, it signifies that a country’s regulatory authority has established a stable, functional, and fully integrated system capable of exercising total control over all medicinal products circulating within its borders. For the people of Bénin, this means uninterrupted access to safe, high-quality, and effective medications.

Beyond public health benefits, the ML3 status carries significant economic and geopolitical advantages. It boosts international trust, encourages local drug manufacturing, and eases export opportunities across Africa. Most crucially, it equips Bénin with a powerful weapon against the scourge of counterfeit medicines, ensuring robust consumer protection.

A decade of reforms reaches its climax

The evaluation’s results were presented to Professor Benjamin Hounkpatin, Bénin’s Minister of Health, who expressed deep satisfaction with the findings. In a public address, he commended the ABMed team for their relentless efforts and the transformative progress achieved. This milestone is no accident—it is the culmination of bold, systematic reforms launched in 2017 to overhaul the pharmaceutical sector.

The government’s strategy included restructuring the former pharmacy directorate into an autonomous agency (ABMed) and tightening legislative frameworks. These decisive actions laid the groundwork for the current success, positioning Bénin as a trailblazer in Africa’s healthcare governance.

West Africa’s next healthcare leader?

This evaluation holds regional implications. Should the final validation confirm the shift to Maturity Level 3, Bénin will join an elite group as the second francophone nation in West Africa to achieve this status, trailing only Sénégal. This achievement would establish Bénin as a future hub of excellence in healthcare regulation across the subregion, proving that with political will and technical rigor, African nations can match the world’s best practices.

A new dawn for public health in Bénin

The WHO’s July 2026 mission marks a historic turning point for Bénin’s public health landscape. While the preliminary indicators are promising, the ABMed teams must now sustain their momentum and implement the remaining recommendations to officially secure the ML3 certification. As Bénin stands on the brink of this achievement, it sends a powerful message: patient safety and pharmaceutical sovereignty are no longer distant goals but an unfolding reality.